Based on the Bicycle Therapeutics Ltd stock forecast from 6 analysts, the average analyst target price for Bicycle Therapeutics Ltd is USD 27.45 over the next 12 months. Bicycle Therapeutics Ltd’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Bicycle Therapeutics Ltd is Slightly Bearish, which is based on 4 positive signals and 5 negative signals. At the last closing, Bicycle Therapeutics Ltd’s stock price was USD 8.73. Bicycle Therapeutics Ltd’s stock price has changed by +12.07% over the past week, -3.85% over the past month and -61.32% over the last year.
No recent analyst target price found for Bicycle Therapeutics Ltd
No recent average analyst rating found for Bicycle Therapeutics Ltd
Company Overview Bicycle Therapeutics Ltd
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase I/II/III clinical trials for the treatment of high nectin-4 expressing tumors; BT5528 (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; and BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that is in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; and Genentech, Inc. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom. Read Less
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin ...Read More
Frequently Asked Questions About Bicycle Therapeutics Ltd (BCYC) Stock
Based on ratings from 6 analysts Bicycle Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on BCYC's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for BCYC is USD 27.45 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 15.
BCYC stock's Price/Earning ratio is 1,839.00.
The last closing price of BCYC's stock was USD 8.73.
The most recent market capitalization for BCYC is USD 0.46B.
Based on targets from 6 analysts, the average taret price for BCYC is projected at USD 27.45 over the next 12 months.
This means that BCYC's stock price may go up by +214.49% over the next 12 months.
We can't find any ETFs which contains Bicycle Therapeutics Ltd's stock.
As per our most recent records Bicycle Therapeutics Ltd has 305 Employees.
Bicycle Therapeutics Ltd's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS.
You can get more information about it from Bicycle Therapeutics Ltd's website at https://www.bicycletherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Bicycle Therapeutics Ltd (BCYC) Stock
Based on ratings from 6 analysts Bicycle Therapeutics Ltd's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has 7 buy, sell and 4 hold ratings.
Unfortunately we do not have enough data on BCYC's stock to indicate if its a good dividend stock.
Based on targets from 6 analysts, the average taret price for BCYC is USD 27.45 over the next 12 months. The maximum analyst target price is USD 38 while the minimum anlayst target price is USD 15.
BCYC stock's Price/Earning ratio is 1,839.00.
The last closing price of BCYC's stock was USD 8.73.
The most recent market capitalization for BCYC is USD 0.46B.
Based on targets from 6 analysts, the average taret price for BCYC is projected at USD 27.45 over the next 12 months.
This means that BCYC's stock price may go up by +214.49% over the next 12 months.
We can't find any ETFs which contains Bicycle Therapeutics Ltd's stock.
As per our most recent records Bicycle Therapeutics Ltd has 305 Employees.
Bicycle Therapeutics Ltd's registered address is Portway Building, Cambridge, United Kingdom, CB21 6GS.
You can get more information about it from Bicycle Therapeutics Ltd's website at https://www.bicycletherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BCYC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
